ArticlePloS one2013
Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Stage-dependent EZH2 methylation correlates with immune polarization, metabolic suppression, and unfavorable outcomes in hepatocellular carcinoma.International journal of medical sciences · 2025Article
- Investigation of CBX4 Polymorphisms and Their Association with Clinicopathological Features in Asian Patients with Oral Squamous Cell Carcinoma.Journal of Cancer · 2025Article
- Analysis of MUC6 polymorphisms on the clinicopathologic characteristics of Asian patients with oral squamous cell carcinoma.Journal of cellular and molecular medicine · 2023Article
- Analysis ofJournal of Cancer · 2022Article
- Analysis of EZH2 Genetic Variants on Triple-Negative Breast Cancer Susceptibility and Pathology.International journal of medical sciences · 2022Article
- Functional relationship of SNP (Ala490Thr) of an epigenetic geneJournal of genetics · 2021Article
- TRIM21 Polymorphisms are associated with Susceptibility and Clinical Status of Oral Squamous Cell Carcinoma patients.International journal of medical sciences · 2021Article
- The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.Journal of cellular physiology · 2018Review
- Effects of four single nucleotide polymorphisms ofOncoTargets and therapy · 2018Article
- Review
- Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.Diagnostic pathology · 2016Article
- Combinations of FUT2 gene polymorphisms and environmental factors are associated with oral cancer risk.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Effects of HMGB1 Polymorphisms on the Susceptibility and Progression of Hepatocellular Carcinoma.International journal of medical sciences · 2016Article
- Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.BMC cancer · 2015Article
- Biomarkers for hepatocellular carcinoma: diagnostic and therapeutic utility.Hepatic medicine : evidence and research · 2015Review
- Genetic alteration and misexpression of Polycomb group genes in hepatocellular carcinoma.American journal of cancer research · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe enhancer of zeste 2 (EZH2) gene encodes the histone methyltransferase that is the catalytic component of the polycomb repressive complex-2, which initiates epigenetic silencing of genes. The expression level of EZH2 in hepatocellular carcinoma (HCC) is highly correlated with tumor progression; however, it has not been determined if specific EZH2 genetic variants are associated with the risk of HCC. This study investigated the potential associations of EZH2 single-nucleotide polymorphisms with HCC susceptibility and its clinicopathologic characteristics. METHODOLOGY/PRINCIPAL
findingsA total of 220 HCC patients and 552 cancer-free controls were analyzed for four EZH2 single-nucleotide polymorphisms (rs6950683, rs2302427, rs3757441, and rs41277434) using real-time PCR genotyping. After adjusting for other co-variants, the individuals carrying at least one C allele at EZH2 rs6950683 and rs3757441 had a 0.611-fold and a 0.660-fold lower risk of developing HCC than did wild-type (TT) carriers, respectively. The CCCA or CCTA haplotype among the four EZH2 sites (rs6950683, rs2302427, rs3757441, and rs41277434), respectively, was also associated with a reduced risk of HCC. Furthermore, HCC patients who carried at least one C allele at rs6950683 or rs3757441 had a higher lymph-node-metastasis risk but a lower liver-cirrhosis risk than did patients carrying the wild-type allele.
conclusionsThe rs6950683 and rs3757441 polymorphic genotypes of EZH2 might contribute to the prediction of susceptibility to and pathological development of HCC. This is the first study to provide insight into risk factors associated with EZH2 variants in carcinogenesis of HCC in Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.